An Open Label Study of the Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers in Subjects With Secondary Progressive Multiple Sclerosis
Latest Information Update: 06 Nov 2021
Price :
$35 *
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Pharmacokinetics
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
- 21 Mar 2017 Status changed from active, no longer recruiting to completed.
- 10 Nov 2016 Planned End Date changed from 1 Jan 2017 to 1 Mar 2017.